Form 4: Humacyte Director Receives Stock Option Grant

Director Susan Richards Windham-Bannister was granted 80,000 stock options in Humacyte, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Susan Richards Windham-Bannister acquired 80,000 stock options in Humacyte, Inc. (HUMA).
• The options have an exercise price of $1.08 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• Vesting begins on June 11, 2027, with 25% of the options becoming exercisable, followed by monthly vesting of 1/48th of the total grant through June 11, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard corporate governance and compensation practices.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• The exercise price of $1.08 may be subject to market fluctuations relative to the future trading price of HUMA.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant structure follows standard multi-year vesting schedules common among mid-cap and small-cap biotech firms.
• The use of stock options as a primary retention tool for board members is consistent with industry norms for companies in the clinical development stage.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first 25% of options on June 11, 2027.

Key Dates

Keywords

Humacyte, HUMA, Form 4, Stock Options, Director Compensation, Insider Transaction